Prelude Therapeutics
PRLD
60 hedge funds and large institutions have $113M invested in Prelude Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
9% more funds holding
Funds holding: 55 → 60 (+5)
13.57% less ownership
Funds ownership: 80.37% → 66.8% (-14%)
36% less capital invested
Capital invested by funds: $176M → $113M (-$63.1M)
75% less call options, than puts
Call options by funds: $1K | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$1.31M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$988K |
| 3 |
BlackRock
New York
|
+$785K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$333K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$301K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$13M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.03M |
| 3 |
Millennium Management
New York
|
-$280K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$180K |
| 5 |
Renaissance Technologies
New York
|
-$165K |
PRLD Hedge Fund Activity: Q3 2023 in Review
60 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q3 2023, worth a combined $113M — down 36% from $176M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PRLD positions and 2 closed out — a net gain of 5 holders — while 24 added to existing stakes and 16 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $1.31M. The largest seller was UBS AM, exiting entirely with an estimated $13M sold.
- 60 institutional investors held Prelude Therapeutics (PRLD) as of Q3 2023, up from 55 in Q2 2023.
- Funds reported $113M of Prelude Therapeutics stock for Q3 2023, down 36% quarter-over-quarter.
- 7 funds opened new Prelude Therapeutics positions in Q3 2023 and 2 closed out, a net change of +5 holders.
- The largest Prelude Therapeutics buyer in Q3 2023 was Sio Capital Management, an estimated $1.31M added.
- The largest Prelude Therapeutics seller in Q3 2023 was UBS AM, an estimated $13M sold.
Based on aggregated 13F filings for Q3 2023.